Free tool
FAERS Monitor: Lumakras
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214665 or its brand name (Lumakras, Sotorasib). Reports on generic versions are filed under their own applications.
Reports
3,470
Serious
2,851
82% of reports
Hospitalization
705
Death reported
824
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- non-small cell lung cancer520
- death415
- disease progression348
- diarrhoea334
- off label use268
- fatigue119
- nausea119
- hepatotoxicity103
- hepatic function abnormal101
- non-small cell lung cancer metastatic98
- lung neoplasm malignant85
- alanine aminotransferase increased81
- aspartate aminotransferase increased80
- decreased appetite77
- drug ineffective75
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 198 |
| 2022 | 714 |
| 2023 | 1,226 |
| 2024 | 545 |
| 2025 | 381 |
| 2026 | 406 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,689 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| non-small cell lung cancer metastaticSignal | 98 | 761.2 | 618.6 | 65,438 |
| non-small cell lung cancerSignal | 520 | 737.9 | 678.0 | 340,596 |
| hepatotoxicitySignal | 103 | 28.2 | 23.3 | 2,662 |
| disease progressionSignal | 348 | 17.9 | 16.2 | 5,543 |
| hepatic function abnormalSignal | 101 | 16.4 | 13.6 | 1,449 |
| lung neoplasm malignantSignal | 85 | 12.6 | 10.2 | 893 |
| aspartate aminotransferase increasedSignal | 80 | 9.1 | 7.4 | 573 |
| alanine aminotransferase increasedSignal | 81 | 8.0 | 6.5 | 490 |
| diarrhoeaSignal | 334 | 3.1 | 2.8 | 499 |
| deathSignal | 415 | 2.9 | 2.7 | 544 |
| decreased appetiteSignal | 77 | 2.0 | 1.6 | 38 |
| off label use | 268 | 1.9 | 1.7 | 109 |
| fatigue | 119 | 0.9 | 0.8 | 1 |
| nausea | 119 | 0.9 | 0.8 | 1 |
| drug ineffective | 75 | 0.3 | 0.3 | 99 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.